CRA’s Rare Disease Spotlight team is excited to present Project LEOPARD, an ongoing assessment of the long-term evolution and outlook for patient access in rare disease. In this first installment, Cécile Matthews and Bhavesh Patel explore what we can expect for patient access in established, or competitive, rare diseases, and how life sciences companies can successfully navigate the future environment for this category of rare disease. Learn more about Project LEOPARD and subscribe to our rare disease insights.
CRA names Patrick Hillan vice president, expanding Life Sciences commercial strategy expertise
“I am happy to welcome Patrick to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He has deep expertise in medical...